Controversy surrounding the use of polypropylene mesh to treat stress urinary incontinence (SUI) and pelvic organ prolapse (POP) continues and has entered a new phase, with large healthcare companies withdrawing from the area of female pelvic floor surgery either partially (Perigee, Johnson & Johnson) or completely (Astora Womens Health; formerly American Medical Systems). This has occurred because of adverse publicity and cost of medical ligation mainly in the USA. We have covered this issue previously in an editorial and debate [1] but feel further discussion is warranted, having reached this new stage.
The debate previously mainly centred on the use of synthetic mesh in vaginal POP surgery but has now spilled over into the use of mesh in all areas of pelvic reconstruction surgery, including SUI and abdominal POP surgery. This ligation against doctors and device companies has led many doctors to stop using these products and a number of large companies withdrawing from this area of medical endeavour altogether. To non-US residents, the litigation payouts of many millions of dollars seem totally out of proportion to the injury suffered. One example of this is payout of US $13.5 million for a recurrent vaginal tape exposure against Johnson & Johnson [2]. Despite litigant lawyers successfully arguing that Bthe TVT [transvaginal tape] was never properly analysed or verified by anyone,^the TVT has been extensively investigated and has a long history of effectiveness and safety and is considered by many to be the greatest development in urogynaecolgy in our lifetime. There now seems to be a real risk that the use of both polypropylene slings and mesh devices in POP may be lost, especially in the USA.
For whatever the pros and cons of mesh usage in SUI and POP, or mistakes made by clinicians or commercial companies in the development and implementation of products, women with pelvic floor problems worldwide will surely be the ultimate losers by withdrawal of these reputable companies from this area. We need innovation in medicine and more effective and safer ways of treating and-better stillpreventing disease. New developments need to be assessed in a scientifically sound way before their widespread use by clinicians. Implementation should only occur once adequate training and accreditation has occurred so as to minimise risks to women. How the procedure is performed is just as important as what procedure is performed.
In this issue of the journal, we published two opinions: one from Europe and one from the USA. There have been mistakes made by manufacturing companies in the development and commercialisation of devices, by the over-ready use by less experienced doctors, and by the failure of supervision by regulatory bodies. There is considerable variation around the world in the attitudes of doctors and the law, the use of mesh POP products, and even the prevalence of POP surgery. Haya et al. reported that In Organisation for Economic Co-operation and Development (OECD) countries in 2012, grafts were used in 15.7 % of anterior vaginal POP repairs and 8.5 % of posterior repairs; the median rate of transvaginal graft use per 1000 women decreased by 3.7 % from 2010 to 2012 [3] . In Germany and France, graft usage is high, with almost one in three used in anterior repairs, 15 % in the USA and 3 % in Canada and the UK. The largest reduction in transvaginal graft usage occurred in the United States, with a 47 % reduction during that time. During the same period, there was a 25.5 % increase in sacral colpopexy performed worldwide [3] . Interestingly, the same polypropylene mesh is used for both vaginal and abdominal procedures, and not surprisingly, similar complications occur, including vaginal mesh protrusion. The incidence is less following abdominal surgery, as the vagina is not opened.
Many device companies are based in the USA, so what happens there has a disproportionate effect on the rest of the world. In the USA, the use of mesh for POP has reduced significantly, reflecting the US Food and Drug Administration (FDA) announcement and ligation, but also there has been poor publicity and the demonization of these products on the Internet, so that the small minority of dissatisfied patients are heard out of proportion to the silent majority who are satisfied. When we reviewed 1225 consecutive women who had synthetic midurethral slings over a 10-year period in our department, the overall subjective cure rate was 85 % (primary sling group 86 %, repeat sling group 62 %). Of the primary sling group, 94 % and 81 % of the repeat group responded yes to the question: BWould you recommend this operation to someone else with incontinence?^ [4] . Synthetic midurethral slings for SUI and transvaginal synthetic mesh for POP should not be viewed as a single entity. Synthetic midurethral slings have a long history of effectiveness and safety, while the risk/benefit profile is less clear for transvaginal mesh for POP. In this issue Ow et al. [5] reported the results of surgery for women with recurrent POP who had a native-tissue repair or transvaginal synthetic mesh. The benefit of using synthetic mesh was a reduced need for further POP surgery, but this was negated by a higher incidence of revision surgery, which was mainly for vaginal mesh protrusion.
So what can or should be done? The focus must as always be what is best for our patients, and we as their doctor must be their advisors and advocates. All surgery has risks and benefits that need to be weighed with full knowledge of the issues involved. Patients cannot be expected to completely understand these complex issues, so medical advice is needed. International and national societies need to voice their opinions after careful consideration of all the facts. This has been done by the International Urogynecology Association, the American Urogynecology Society, the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction, as well as many national colleges and societies.
Finally, there is much disinformation out there. It is more important than ever to give our patients comprehensive unbiased information of the risks and benefits of any operation we plan to do so they have a realistic overview before making their decision.
